Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Rakuten Medical’s Photoimmunotherapy Platform Renamed Alluminox
March 9, 2022
- Nobelpharma, Toyo Ink Tie Up on Biologics Development, Overseas Expansion
March 9, 2022
- Nippon Chemiphar Gets Japan Sales Rights to Another Delta-Fly Cancer Med
March 9, 2022
- Astellas’s Hot Flash Drug Fezolinetant Delivers Positive PIII Data
March 8, 2022
- SanBio’s Sakigake Cell Therapy Finally Filed in Japan for Traumatic Brain Injury
March 8, 2022
- Gazyva-Calquence Combo Filed in Japan for CLL: Chugai/AstraZeneca
March 8, 2022
- Japan Ethical Drug Sales Up 5.8% in January: Crecon
March 8, 2022
- Oncolys, NIID Team Up to Unlock Oral COVID-19 Med’s Mechanism of Action
March 8, 2022
- Big 3 Japan Generic Makers See Average 8.2% Price Cut in FY2022: Jiho Poll
March 7, 2022
- Shionogi’s COVID-19 Jab Non-Inferior to Pfizer Shot in Japan Booster Trial
March 7, 2022
- Eisai Suffers 9%-Plus Cut, Sumitomo Dainippon Over 8% in 2022 Drug Price Revision: Jiho Poll
March 7, 2022
- Eisai Begins Data Submission for Lecanemab for Swift Approval in Japan
March 7, 2022
- AZ Japan Working towards 100% Electric Vehicle Fleet by 2025, but Challenges Remain
March 3, 2022
- Sumitomo Dainippon to Succeed Fabrazyme Biosimilar Sales from JCR
March 2, 2022
- Trulicity, Rybelsus Might Gain Ground in GLP-1 Market amid Ozempic Supply Woes
March 2, 2022
- Astellas Returns Rights for Pneumococcal Vaccine to Affinivax on Strategic Prioritization
March 2, 2022
- Sanwa Kagaku Bags Japan Rights to Crinetics’ Paltusotine
March 2, 2022
- EA Pharma Licenses Secondary Hyperparathyroidism Drug to US Firm
March 2, 2022
- Key EU Panel Backs Padcev Again for Bladder Cancer
March 2, 2022
- Zogenix Sees Its Pipeline Drugs Continue to Be Developed in Japan after UCB Deal
March 2, 2022
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…